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1. Introduction  
 
Chronic itch is a prominent symptom of  numerous skin diseases, in addition to certain neuropathic and 
systemic conditions 135. Common conditions presenting with itch include atopic dermatitis (AD), 
psoriasis, post-herpetic neuralgia, kidney failure, and liver diseases 34,148,158,159. Similar to chronic pain, 
chronic itch often presents with additional somatosensory abnormalities 10,34,65,109. As such, patients with 
chronic itch are often bothered by mechanical itch dysesthesias, warmth-evoked itch exacerbations, pain, 
stinging, pricking and/or burning skin sensations 10,34,45,68,140,161. Itch dysesthesias refer to dysfunctional 
sensory states, in which considerable itch is evoked by light tactile stimuli (e.g. from clothing or touch), 
or by stimuli which would normally induce only mild itching or pain 10,21,65,124 (Fig. 1A and B).  
 
As early as 1938 Bickford described that immediately surrounding an itch provocation (such as a 
histamine skin puncture), an area where innocuous mechanical stimulation produces itch developed. He 
termed this phenomenon “itchy skin” 31. The alternate, more precise term “alloknesis” was later coined by 
LaMotte et al. in 1988 when revisiting and extending on Bickford’s findings 31,79,81. Moreover, the term 
“hyperknesis” was proposed to act as an umbrella term also encompassing the state in which there is 
enhanced itch to normally itch-provoking stimuli or lowered itch threshold to a given stimulus 36,79,81,131 
(comparable to hyperalgesia for pain 64). These dysesthetic states may last for a couple of minutes to 
hours after an itch provocation or can be a persistent feature, as seen in patients with chronic itch due to 
AD 10,63,65. Itch-associated dysesthesias such as mechanical alloknesis and hyperknesis, are noticeably 
analogue to the dysesthesias found in various experimental and clinical pain conditions 68,124,134. For 
instance, while patients with painful peripheral neuropathy may report pain in response to light innocuous 
brush strokes applied to the skin in or around painful areas (allodynia), patients with chronic itch 
conditions frequently find such stimuli to be itchy (alloknesis) 8,63,124.  
 
Such somatosensory reactivity patterns are caused by neuronal sensitization, and those signs associated 
with pain (allodynia and hyperalgesia) have been elaborately studied both mechanistically 123,151, and in 
diverse clinical cohorts (covered in detail elsewhere 19,24,37,86,119). Therefore, much of the present 
methodological, phenomenological and mechanistic evidence on mechanical allo- and hyperknesis stems 
from obvious parallels related to pain-associated dysesthesias as well as from preclinical and human 
experimental models of itch 8,21,79,81,124,130,132. Notably, the neurophysiology of itch transmission is highly 
entwined with the nociceptive system, with no clear differentiating features at the peripheral level. This 
has given rise to different hypotheses explaining how pruriceptive and nociceptive information coming 



































































  2 
In pain research, highly standardized quantitative sensory testing (QST) methodology 20,55,92,156 and 
diverse human models of sensitization has spawned the notion of potential sensory phenotyping for 
diagnostic, prognostic and therapeutic purposes 18,22,24. The assessment of alloknesis and hyperknesis 
allow for surrogate measures of neuronal sensitization in itch patients. However, itch-specific QST 
protocols are much less advanced and studied compared to pain. It remains to be explored whether 
assessment of itch sensitization correlates is useful for the purpose of subgrouping, for instance in patients 
with AD, akin to the sensory phenotyping being utilized within pain research 24,46,139,157. The purpose of 
this review is to provide an overview of the definitions, present evidence regarding assessment 
techniques, and mechanisms of mechanical allo- and hyperknesis, while linking this evidence to the more 
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2. Definitions and terminology 
Allodynia and hyperalgesia (the pain-related equivalents to alloknesis and hyperknesis) have been defined 
and redefined on several occasions 64,89,95–97,123. The present review adheres to the IASP taxonomy task 
force definitions of 2008 (elaborately described by, e.g., Loeser and Treede 89,138, and Sandkuhler 123). 
These definitions are not in full agreement with the current IASP definitions (the updated version of the 
1994 taxonomy64).  
Hyperalgesia (“increased pain sensitivity”) is characterized as an umbrella term describing all types of 
increased pain sensitivity while the term; allodynia (“pain in response to a non-nociceptive stimulus”) is 
restricted to scenarios where the nature of the evoking stimulus is such that it is deemed unable to activate 
nociceptive primary afferents 96,123,138. This review uses a similar definitional principle for allo- and 
hyperknesis, i.e. using hyperknesis whenever there is doubt as to the prompting stimulus’ capability of 
activating pruriceptive afferent (See Fig. 1A and B). This is also generally in accordance with the original 
definitions 79,81.  
 
In the literature conflicting nomenclature is currently being used to describe allo- and hyperknesis 
phenomena. Some studies describe alloknesis solely as itch occurring in response to innocuous (dynamic) 
tactile stimuli, and hyperknesis only as itch in response to punctate pricking stimuli, which may or may 
not be considered mildly painful under normal conditions 63,111 (see Table 1). Other studies denote 
alloknesis as itch in response to punctate von Frey stimuli, e.g. up to 70 mN force 1,33,107 (i.e. far above the 
threshold for activating mechano-sensitive C-nociceptors). Other reports describe assessments of 
‘mechanical itch sensitivity’, using von Frey filaments in chronic itch patients or after acute itch 
provocations, omitting the terms alloknesis or hyperknesis 13,75,77,78. Discrepancies exist regarding the 
extent to which these stimuli are reported to produce itch under normal conditions, and sometimes this is 
not assessed. It has also been noted that hyperknesis could simply refer to an exaggerated response to 
chemical stimuli, such as increased itch following histamine, as have been observed in lesional AD skin 
54,67,79, but this usage has never caught on. The definitions applied in the present review prevent that a 
unitary occurrence, such as increased itch sensitivity to punctate mechanical stimuli or chemical itch 
provocations, as being classifiable as both alloknesis and hyperknesis at the same time, depending on how 
it is tested (threshold vs. suprathreshold assessments).  
 
Recently, ‘alloknesis’ has been used to characterize itch and itch aggravation in response to noxious heat 
and innocuous warmth stimuli 38,102. Future research might clarify whether gentle warming-induced itch is 
indeed a type of alloknesis 102 or whether it is an itch-related analogue to inflammatory hyperalgesia. The 


































































  4 
stimuli, is not includable in current definitions of alloknesis and hyperknesis (See Table 1). It has been 
observed in patients with AD, in healthy subjects with evoked contact dermatitis and in mice models 
5,38,102 and is not associated with any specific term. In this review the term algoknesis will be applied to 
describe this sensory phenomenon, which conceivably rely on mechanisms distinct from those of 
hyperknesis and alloknesis. Itch in response to noxious heat, e.g. observed in AD patients will 
accordingly be characterized as ‘heat algoknesis’.   
 
3. Mechanisms of alloknesis and hyperknesis 
 
Given the similarities between itch and pain-evoked dysesthesias, it is natural that aspects of the proposed 
underlying mechanisms are based on similar experimental approaches and inferences 68,80,124. Alloknesis 
and hyperknesis typically occur within the region of an itch provocation, and in the skin immediately 
surrounding the provocation site. Consequently, the dysesthesias are referred to as being primary and 
secondary, respectively. Mechanistically, two potentially overlapping sensitization processes exist; 
sensitization of spinal neurons (central sensitization) and sensitization of the peripheral neurons 
(peripheral sensitization). In a state of central itch sensitization, pruriceptive spinothalamic tract (STT) 
neurons respond more vigorously to normal input from pruriceptive primary neurons and afferent 
mechanosensitive signaling, normally associated with light touch (alloknesis) or mild pain/itch 
(hyperknesis) converges onto the STT neurons (Fig. 2A and B for models) 82,123. The corresponding pain 
phenomena (i.e. secondary allodynia and hyperalgesia) also rely on sensitization of STT neurons 132. 
These pain dysesthesias do not cross the midline 83 or extend beyond a narrow anesthetized strip of skin 
72, are reduced or abolished by myelinated fiber blocks 73,90,163 and are mostly unaffected by ablation of 
capsaicin-sensitive nociceptors 57,90,163. This all indicates that secondary allodynia and hyperalgesia are 
segmentally restricted, heterosynaptic, spinal sensitization phenomena which rely on initial intact input 
from mechano-sensitive, TRPV- fibers. However, in prolonged inflammatory/neuropathic pain and itch 
states, additional or entirely different mechanisms potentially relying more on peripheral sensitization, 
disinhibition and supraspinal changes, may also be involved 22,84,123. Strong indirect evidence on the close 
link between itch and pain-evoked dysesthesias comes from experimental human psychophysical studies. 
When a conditioning painful stimulation such as an intra-dermal capsaicin injection 36, or painful 
transcutaneous electrical stimulation 106,107 is pre-applied to a skin area it will exhibit decreased itch 
sensitivity and inhibited itch dysesthesia development long after the spontaneous pain resolves.  This may 
in part be due to the fact that the same neuronal substrates are recruited in the sensitization processes, e.g., 
low-threshold mechano-receptor (LTM) input to sensitized STT nociceptive and pruriceptive projection 


































































  5 
chronic itch associated with AD, substantial itch and pain can co-exist in lesional skin 10,140 and the same 
is true for robust mechanical hyperalgesia and hyperknesis 10.   
 
3.1 Alloknesis: In non-human primates, injection of histamine results in a small number of pruriceptive 
STT neurons exhibiting increased responses to stroking (alloknesis), or to a punctate skin stimulus 
(hyperknesis), evoking mild pricking pain sometimes followed by itch in humans 43,129. As outlined 
above, itch evoked by brush strokes represents a central sensitization phenomenon of wide dynamic range 
STT neurons resulting from an initial PmC or C-mechano-insensitive (CMi)-mediated pruriceptive 
barrage (see Fig. 2A and Table 1). This is circumstantially supported by the fact that the primary afferent 
substrate for light touch is LTMs (Aβ- and C-tactile fibers) and that this type of stimulation rarely results 
in itch under normal conditions. In this context, it is important to note that in trigeminally innervated 
areas very low intensity mechanical stimuli (such as those used to assess alloknesis or minute vibration of 
a vellus hair), are sufficient to produce an itch or tickle sensation 11,49. Remarkably, the same trigeminal 
skin areas exhibits decreased sensitivity to common chemical itch provocations 11,49,91. A recent rodent 
study quantifying alloknesis by low intensity von Frey filaments suggested that mechanically evoked itch 
might be mediated by LTMs, and showed that such itch is constantly gated by a subpopulation of 
inhibitory neuropeptide Y+ interneurons under normal conditions 33. Experiments on allodynia in non-
human primates show that capsaicin-induced mechanical allodynia occurs in the absence of increased 
sensitivity of the nociceptive primary afferents 27, while STT neurons exhibited enhanced responsiveness 
to normal input 132; thus strongly suggesting central sensitization and subsequent increased convergence 
to be the driving mechanism. It has recently been shown that not only the STT but also the 
spinoparabrachial pathway is involved in ascending itch transmission 101. It remains unknown whether 
these projection neurons are also involved in mediation of itch sensitization. A large proportion of 
neurons in both the STT and spinoparabrachial pathway express the neurokinin-1 receptor 137. When these 
neurons are selectively ablated robust inhibition of alloknesis is observed AD mice 6, thus potentially 
implicating both ascending pathways.  
Notably, areas of alloknesis (and allodynia) rapidly retract when cooling the site of spontaneous itch/pain 
indicating that at least weak constant pruriceptive C-nociceptor input is required 111,131. This observation 
aligns with evidence from chronic itch patients where alloknesis is restricted to lesional and peri-lesional 
skin 63. Pharmacological modulation studies in mice and humans show that the μ-antagonist naltrexone 
inhibits itch and the development of alloknesis 1,58,116, while systemic μ-agonist analgesics generally 
induce or aggravates itch and exhibits anti-allodynic effects 30,74,125. The exact spinal circuitry that 
mediates secondary alloknesis, hyperknesis as well as secondary pain dysesthesias remains to be fully 
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3.2 Hyperknesis: The mechanisms of hyperknesis are less clear, and it remains unknown which type of 
afferents mediate the mild itch resulting from punctate stimuli 49,66. Hyperknesis is possibly mediated by 
type-I Aδ-fibers through a central mechanism when occurring secondarily to an itch provocation or an 
actively itchy skin lesion, as is the case for secondary pinprick hyperalgesia (Fig. 2B). On the other hand, 
itch evoked by pricking stimuli occurs with a 0.5-2 second delay 13,65, indicating PmC-fibers as the 
peripheral sensor (Table 1). When pinprick hyperknesis occurs within an active skin lesion or an area 
pretreated with an itch provocation, additional peripheral contribution is possible 10,63,65. In the case of an 
inflammatory perturbation, mechanically insensitive afferents can develop de novo mechanosensitivity 
and mechano-nociceptors respond more vigorously to suprathreshold stimuli 17,98,117. In chronically itchy 
AD lesions (and to a lesser extend beyond the lesions) profound pinprick-evoked hyperknesis occurs, 
suggesting concomitant peripheral and central sensitization contributions 10,65,75. A sub-population of 
nociceptors potentially responsible for punctate mechanically evoked itch are the non-peptidergic mas-
related G-coupled protein receptor D (MrgprD)-expressing C-fibers. These terminate very superficially in 
the epidermis 164, are implicated in non-histaminergic itch 87, have low mechanical thresholds 152, and are 
sensitized to punctate stimuli in a mouse model of contact dermatitis 117. The same contact dermatitis 
model also produces robust pinprick hyperknesis in humans 111. In AD, intra- and extra-lesional itch 
sensitization to chemical provocations (algogens 63 and pruritogens 10,56,67,75,136), is mechanistically 
unaccounted for, possibly reflecting protracted cutaneous aberrations. A study has suggested altered 
transducer expression, e.g. increased proteinase-activated receptor-2 (PAR2) on afferent nerve fibers in 
lesional AD skin 136. It is unlikely that current acute human models of itch sensitization mimic the sensory 
aberrations associated with prolonged or chronic inflammatory lesional and related skin alterations 8,65. 
Notably, inflammatory heat hyperalgesia is overwhelmingly driven by peripheral sensitization 98, but this 
is rather different from the sensory abnormalities found in lesional AD skin 65, where normally painful 
heat stimuli evoke itch, and innocuous warming of the skin often exacerbates ongoing itch 10.  The latter 
observation has been successfully reproduced in rodent itch models and is thought to predominantly occur 
following provocations with specific pruritogens such as serotonin 53,102. Human surrogate models known 
to induce sub-acute peripheral pain sensitization, such as UVB-damage (inflammatory) and intra-dermal 
NGF (non-inflammatory), both induce mild primary pinprick hyperknesis at baseline but have limited 
impacton chemical itch provocations 16. The well-studied mechanical hyperalgesia of these models differs 
from that of intradermal capsaicin, as it is driven by peripheral sensitization and associated with 
no/limited spontaneous pain. According to one study, the NGF model do evoke increased sensitivity to 
cowhage occurring simultaneously with the maximal mechanical hyperalgesia, indicative of sensitization 


































































  7 
A complicating factor in term of understanding hyperknesis, is that the manner in which itch and pain are 
differentially encoded (allowing PmC-nociceptors to be both pruriceptive and nociceptive), remains 
unknown. If the proposed notion of spatial contrast is indeed a crucial encoding component for 
discrimination between itch and pain 103,104, then the mechanism for hyperknesis in lesional skin of 
patients with itch could simply be either be highly scattered loss of PmC-fibers (as indicated by nerve 
morphology studies in chronic itch patients 114), or sensitization of a small subset of PmC-fibers. Both of 
these scenarios would likely increase itch in response to pinprick stimuli by giving rise to signaling with 
unusually high spatial contrast.  
 
4. Quantitative assessment of mechanical alloknesis and hyperknesis 
 
4.1 Animal studies: Alloknesis is assessed by eliciting scratching in response to low intensity mechanical 
stimuli that would not normally elicit scratching for instance in C57BL/6 mice (Table 2) 1. After 
intradermal injection of certain pruritogens into the rostral back, a very weak von Frey filament (0.7 mN) 
is applied to the skin area around the injection site. The presence or absence of an evoked hind limb 
scratch bout directed toward a site of innocuous touch is noted. Touch-evoked scratching is usually 
observed less than a second after the stimulus. Pharmacological validation of this assessment method has 
been done by showing effective abolishment of alloknesis after treatment with opioid antagonists, 
selective κ-opioid-agonists and H1 histamine antagonists (when the chemical itch provocation is 
histamine-dependent) 1,2,58. The onset of alloknesis is often delayed relative to the onset of chemically 
evoked scratching, implying that substantial constant itch input is required to develop alloknesis. Touch-
evoked scratching after innocuous stimuli is also present in experimental mouse models of chronic itch 
(Table 2). In humans alloknesis is often assessed by brush strokes (section 4.2) and although brush-
evoked scratching has not yet been reported in rodents, pruriceptive signaling in response to brush stimuli 
is enhanced following an intrathecal injection of morphine in rat pruriceptive trigeminothalamic tract 
neurons 100.  
 
Mechanical hyperknesis has not been clearly established in rodents, due to the lack of a standardized 
method to assess a mechanical itch threshold in naive rodents. Mechanically evoked itch in response to 
graded stimulation, peaks below the force of the mechanical pain threshold in humans (as well as the 
minimum force normally required to activate PmC-nociceptors) 11,65. Additionally, the relationship 
between mechanical force and evoked itch intensity follows an inverted U-shaped curve. One study 
reported that few scratch bouts were elicited by application of graded von Frey filaments in naive mice 33, 
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elicited in response to less than 15% of the stimuli. A fundamental difference regarding the quantification 
of itch is that animal readouts are always scratch-dependent. Oppositely, humans can easily rate an 
evoked itch sensation, which is so mild that it would rarely elicit an actual scratch. In human studies this 
is almost always the case for the mechanically evoked itch in healthy skin 9,65,77. Lastly, as there are 
rodent strain differences in mechanical sensitivity 99, the mechanical itch thresholds should be assessed in 
each strain tested. Outbred mouse strains might not be suitable for pre-clinical studies of mechanical itch 
due to their genetic heterogeneity.  
 
4.2 Human experimental studies: Using human surrogate models of acute and sub-acute itch, detailed 
assessments of allo- and hyperknesis to mechanical stimuli can be undertaken (Table 2). Intradermal 
injection, a skin prick, or iontophoretic delivery of a pruritogen such as histamine, mucunain, or serotonin 
evokes acute itch lasting 5-20 minutes 8,62,131. During, or as the itch subsides, the spatial extent of 
alloknesis and hyperknesis can be assessed by stimulating the skin surrounding the injection site 
66,111,131,149. Alloknesis is commonly assessed using a light brush, while hyperknesis is often assessed with 
a pinprick stimulator or von Frey monofilaments 66,111. Typically, stimuli are delivered in small 
increments (0.5-2 cm) following multiple vectors moving from well away from the injection site and 
towards it. The subjects are asked to notify the investigator when the stimuli turn from producing pure 
innocuous tactile sensations into itch (alloknesis) or from a pricking/slightly itchy to evoking noticeably 
more itch (hyperknesis) 131. This procedure can be repeated in short succession (as areas of alloknesis and 
hyperknesis are dynamic) to decrease variability and produce an accurate spatial mapping of the extent of 
allo- or hyperknesis. The drawbacks are that it is: 1) time consuming; 2) vulnerable to false positives (a 
control is always required); and 3) relies on a localized initial itch provocation (making it difficult to 
apply to endogenously evoked itch in patients). Alternatively, the intensity of the allo- and/or hyperknesis 
can be assessed in the immediate vicinity of an itch provocation 11,63,75,111. Here, the stimulation is 
conducted several times, with multiple intensities close to the itch provocation site, but usually not 
immediately on the bleb or wheal. The subject is asked to rate the presence and/or the intensity of the 
mechanically evoked itch 10,63,67. The intensity, or simply the presence of alloknesis, can be quantified in 
response to brush strokes or cotton wool stimuli and the intensity of hyperknesis in response to von Frey 
or pin prick stimuli 11,63. Evidence suggests that punctate stimuli around or immediately below the 
pinprick pain threshold are most effective, and do also occasionally produce mild itch in unaffected skin. 
This method is faster than the area approach but does not detect the spatial outline of the assessed 
dysesthesias and relies on the subject providing a magnitude rating rather than simply a shift in 
perception. On the other hand, the method lends itself more readily to be used, e.g. on lesional, peri-
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provocations or interventions as well as to assess the temporal development of itch dysesthesias. These 
methods are entirely paralleled by the techniques used in pain research 120,130, where experimentally 
provoked allodynia and hyperalgesia have been extensively studied. In pain research, these methods have 
been used for instance in an attempt to measure objective correlates of central sensitization 35, or to 
characterize the peripheral nociceptors involved in induction of long-term potentiation-like pain 
facilitation 57.  
 
4.3 Clinical studies: Several studies have performed explorative assessments of allo- and hyperknesis in 
patients with chronic itch in both lesional and non-lesional skin areas as well as before and after 
experimental itch elicitation (Table 3). Generally, one of two methods have been applied in previous 
studies: 1) alloknesis or hyperknesis have been assessed in lesional and/or non-lesional skin of patients 
using an intensity approach, i.e. patients and healthy controls are requested to rate if, and how much itch 
they perceive in response to selected mechanical stimuli (brush, wool fibers or pinprick) 10,65,75; 2) patients 
and controls receive an itch provocation, e.g., histamine or electrically induced itch, in non-lesional skin 
(homologous areas for controls) and subsequently the area of allo- or hyperknesis is mapped as described 
in Section 4.2 66,147,149. A few studies have used the spatial extent method outlined above only after an 
experimental itch induction has been conducted 147,149, excluding the detection of potential baseline 
differences between chronic itch patients compared to healthy controls 63. Both chronic itch and pain may 
lead to generalized somatosensory changes and thus even seemingly unaffected areas are not necessarily 
suitable control areas 52,75,77. For instance, increased hyperknesis, increased mechanical pain sensitivity 
and facilitated itch responses to cowhage provocations were recently observed in non-lesional skin in 
patients with AD, compared to homologous skin areas in matched controls 10. Particularly when 
stimulations are performed in patients with inflammatory skin disorders, barrier alterations must be 
considered as potential as biasing factors completely unrelated to cutaneous neuronal sensitivity. For 
instance, pinprick perception might be altered in lichenified skin 10, responses to chemical provocations 
delivered by iontophoresis might be exaggerated in excoriated areas with reduced barrier integrity, and 
the temporal profile of evoked itch might be affected by increased or reduced vasomotor reactions to 
pruritogens by affecting local tissue clearance 11,67.  
 
 
5. The applicability of itch dysesthesia assessments 
 
5.1 Mechanical itch dysesthesias in patients: Despite diverse assessment methodology clinical studies 


































































  10 
have been performed in patients with chronic itch due to AD. When quantifying the spatial extent of 
alloknesis or hyperknesis following an itch provocation in non-lesional skin, AD patients do not develop 
larger areas of mechanical dysesthesias than healthy controls 59,66,147,149. However, it is evident that when 
using the intensity quantification approach both robust alloknesis and hyperknesis occur in lesional AD 
skin 10,63,65,75, whereas good evidence is lacking from other chronic itch conditions. Results from studies 
applying the intensity quantification approach without prior itch provocation in non-lesional skin of 
patients with AD are more inconsistent. A single study assessing alloknesis found no evidence of it 
occurring in non-lesional AD skin 63. Alloknesis has previously been described in case-studies of 
neuropathic itch patients as occurring peri-focally, restricted to areas of moderate to severe itch 7,15, and is 
likely more or less dependent on ongoing spontaneous itch nearby 111,131. With regards to hyperknesis in 
AD, Ikoma et al. 2004, documented significant lesional and peri-lesional hyperknesis in response to 
weighted needle stimulation, while Laarhoven et al. 2007 and Andersen et al. 2017 observed significant 
hyperknesis in both lesional and non-lesional skin probed using von Frey stimulators (see Table 3). 
Significant inter-variability in the severity of hyperknesis seems evident amongst patients with AD, 
possibly indicating the existence of patient subgroups with high vs. low mechanical itch sensitization 
(Fig. 3A and B) 10. Extra-lesional hyperknesis appears to almost exclusively occur in patients also 
displaying hyperknesis in lesional skin (Fig. 3C and D) 10. In painful peripheral neuropathy a well-
characterized sensory sub-phenotype is characterized by prominent mechanical hyperalgesia, e.g., to 
pinprick stimuli 24. This particular subgroup is proposed to have increased analgesic responses to sodium-
channel blockers and gabapentinoids 24,47.  
 
5.2 Disinhibition as a cause of itch sensitization: Itch, akin to pain, is under both segmental and 
supraspinal descending inhibitory control 26,94. The former is clearly evident from the itch relieve 
obtainable by homotopic or perilesional counter-stimuli such as scratching or heat 14,160, while the latter 
has been shown using conditioned itch modulation paradigms in patients and healthy controls 76 (an 
approach adapted from psychophysical pain research108,154). It is unclear whether blunted responsiveness 
in either of these endogenous inhibitory systems contributes to itch dysesthesias in chronic itch patients. 
However, indications of both reduced segmental inhibition 69,127 (Fig. 2C), and impaired descending itch 
inhibition have been reported 76. Such assessments have been performed with mostly non-validated 
psychophysical methodology. A recent experimental study in healthy human volunteers indicates that 
pain-evoked recruitment of descending inhibitory signaling diminishes not only itch but also the 
development of hyperknesis following electrically induced itch 12. This is in line with evidence from the 
pain field showing that conditioned pain stimulation reduces the intensity of secondary brush-evoked 


































































  11 
lesions and cutaneous pain co-existing with itch in AD 10,34,109,140, it is not unreasonable to suspect blunted 
pain-evoked inhibition in this condition as a previous implied 65,69. This is likely caused by spinal 
disinhibition of itch; e.g., peripheral antinociceptive endogenous opioid expression is decreased in 
inflammatory itch conditions and as pain thresholds are usually normal 10. Validated psychophysical 
assessment methods are needed before it can be established whether dysfunctional segmental or 
supraspinal descending itch inhibition is a feature in chronic itch conditions. Reduced descending pain 
inhibition measured by conditioned pain modulation (CPM) paradigms, has been found in numerous 
chronic pain conditions and is implicated in the pain progression 52,110,154,155. Notably, the effect of drugs 
enhancing endogenous pain inhibition, such as duloxetine, can be predicted by CPM, in that low CPM-
responses correlate with increased analgesia 157. 
 
5.3 Itch sensitization to non-mechanical provocation modalities: In rodents, innocuous warming 
aggravates serotonergic but not histaminergic itch 5. AD patients consistently report that their itch is 
worsened by warmth 10,51,142. However, in acute human models of itch such findings are not reproduced, 
potentially because studies have almost exclusively relied on histaminergic itch provocations not 
mimicking itch in AD 14,48. While studies on itch in response innocuous thermal stimulation in AD are 
inconclusive, heat algoknesis has been documented in patients with AD. Heat stimuli in the noxious range 
applied in lesional skin of patients with AD have been shown to induce itch even when such stimuli were 
consistently rated as evoking only heat pain in the healthy controls 65. Similar observations have been 
made in a human model of contact dermatitis itch 111.  For electrically induced itch the evidence is 
contradictory, with studies showing both no differences in itch ratings between chronic itch patients vs. 
healthy controls, as well as studies showing significant sensitization in itch patients 66,78,162. Itch 
sensitization to chemical provocations with pruritogens 10,67,144 is the most studied phenomenon. While it 
is beyond the scope of the current review to summarize this extensive literature, it appears that evidence 
supports at least two central findings: 1) there is limited sensitization to histaminergic itch provocations, 
perhaps beyond mild sensitization occurring intra-lesionally 67,143,144, and 2) recent studies indicate 
increased intra- as well as extra-lesional sensitivity to cowhage-evoked itch 10,56,113. However, a 
systematic assessment of studies on sensitization to various chemical itch provocations in chronic itch 
patients is needed before more definite conclusions can be drawn. Notably, algoknesis to chemical pain 
provocations is well documented. In lesional skin of patients with AD common algogens such as 
acetylcholine 60, low pH-solution 65 and bradykinin 63 predominantly evokes itch whereas they mostly or 
exclusively evokes pain in healthy controls. Conversely, histamine, which is considered a quintessential 
pruritogen, has been shown to acts as an algogen in patients with chronic post-herpetic neuralgia 25. 
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chronic inflammatory itch conditions, sensitization of pruriceptive units probably include mechanisms by 
which tachyphylaxis is counteracted, which would contribute to maintaining prolonged itch 
exacerbations. A proposed mechanism hereof is that local tissue acidosis (associated with inflammation) 
enhances pruriceptive signaling by co-opting acid-sensing ion channel 3 70. 
 
5.4 The potential implications of measuring itch sensitization: For many patients with chronic itch, 
allo- and hyperknesis are highly bothersome symptoms that prompt, maintain or worsen scratch bouts and 
impose behavioral restrictions, including avoidance of wearing certain fabrics or staying away from warm 
environments 10,28,34,141. It is not clinically feasible to implement microneurographic recordings from 
peripheral neurons and assessing sensitization directly in spinal nociceptive circuitry is impossible in 
humans. Instead, by using QST, the severity and spatial extent of itch dysesthesias and hypersensitivity to 
various sensory stimuli can be psychophysically measured in individual patients 8,10,65,144. Based on case 
descriptions, mapping of allo/hyperknesis has been found useful as a means to locate an itch 
hypersensitive area on normally appearing skin 7,15.  
 
Within the pain research area, assessment of sensitization using standardized QST and advanced sensory 
paradigms, such as temporal summation of pain and conditioned pain modulation, have been shown to be 
useful for instance in predicting treatment response to pharmaceutical and surgical interventions 
24,46,115,157. Notably, recent studies have shown that mechanistic subgrouping of neuropathic pain patients 
based on assessment of, e.g., mechanical and thermal hyperalgesia may result in improved treatment 
response rates 46,93. Such studies have not yet been undertaken in patients with chronic itch, but it is clear 
that centrally acting antipruritics can be of use in otherwise refractory patients 40,116. Moreover, a recent 
study proposed that prolonged itch and micro-vascular reactions to cowhage and histamine provocations 
might act as diagnostic indicators of AD, being of potential value in atypical/mild cases 56. Currently, the 
clinical utility of assessing alloknesis and hyperknesis as well as itch sensitization in general (e.g. 
sensitization to chemical provocations) remains to be explored. Antipruritic therapeutic measures should 
focus on reducing local inflammation and targeting the underlying cause when possible. In contrast to 
chronic pain, chronic itch is mainly regarded as a symptom of an underlying disease rather than as a 
disease itself. However, chronic itch also presents in absence of any recognized disease processes, in 
which case it is often denoted as chronic idiopathic pruritus 29,153. Disease measures such as lesional 
severity in AD correlates surprisingly poorly with the itch and cutaneous pain that the individual patients 
report 41,146. An analogue mismatch between pathological findings and pain symptoms is commonly 
observed in pain conditions 19,50. It could be hypothesized that chronic itch patients with inflammatory 
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responses to chemical provocation in non-lesional skin, would respond adequately to peripherally acting 
anti-inflammatory and immune-modulatory drugs. On the other hand, patients exhibiting significant intra- 
and extra-lesional itch sensitization, could benefit more from additional therapeutics inhibiting central 
itch processing as well as sensitization 67. Evidence from the pain field suggests that centrally acting 
pharmacotherapy inhibiting central hyper-excitability in addition to cognitive behavioral-, stress-relief- or 
exercise therapies might be effective in reducing sensitization. Relevant pharmaceuticals include NMDA-
receptor antagonists, opioids, tricyclic antidepressants, selective-serotonin reuptake inhibitors (SSRI), 
serotonin noradrenaline reuptake inhibitors and gabapentinoids 23,24,39,105. Notably, despite a scarcity of 
RCTs with itch relieving drugs, both SSRIs and gabapentinoids have antipruritic effects in certain itch 
conditions while opioids (μ-agonists) are well known to induce itch 116. Several studies have associated 
psychophysical measures of pain sensitization with treatment outcome following both pharmaceutical and 
surgical interventions 46,93,115,157. Such data is currently lacking in the context of itch and it is unclear 
whether similar mechanistic inferences can be drawn from itch sensitivity testing. While alloknesis and 
hyperknesis are commonly referred to as prominent features of chronic itch conditions 124,134, they have 
thus far only been sparsely studied in other chronic itch patients groups than AD 59,65,75,77,144. Assessing 
the clinical utility of itch sensitivity quantification requires developing a standardized, compact 
psychophysical test battery designed to detect and measure itch sensitization in patients 92. Such tests need 
to be based on, and optimized in accordance with, advances in our mechanistic understanding of itch and 
itch sensitization to mechanical and other types of stimuli. Concerns have recently been expressed 
regarding the degree to which the nociceptors responsible for spontaneous pain, for instance in 
neuropathic conditions, are specifically testable with currently applied sensory assessment protocols 32,126. 
Data from pain patient cohorts obtained by QST paradigms such as sensory pain thresholds does only 
occasionally correlate well with the reported clinical pain 118,126,133,157. As similar caveats might adhere to 
itch sensitivity assessments, it is by no means a foregone conclusion that sensory testing is clinically 
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6. Conclusion  
 
Cutaneous dysesthesias associated with itch and pain are strikingly similar, and can be assessed by similar 
sensory testing techniques, acting as proxy measures of sensitization. For pain, assessment of allodynia 
and hyperalgesia are ubiquitous in probing the nociceptive system in preclinical, experimental, and 
clinical settings. Clinically, this may be used to inform/predict responsiveness to treatment. In contrast, 
assessment of itch-associated dysesthesias has only been marginally studied. Quantifying alloknesis and 
hyperknesis provides behavioral or psychophysical proxies of itch sensitization which can be performed 
in animal and human surrogate models of itch, as well as in patients. This review provides a 
comprehensive overview of: 1) the definitions and purported mechanisms of alloknesis and hyperknesis 
and their analogy to pain sensitization phenomena; 2) the methods by which alloknesis and hyperknesis 
can be quantified in preclinical, human experimental and clinical studies; 3) results derived from studies 
of alloknesis and hyperknesis in chronic itch patients, and; 4) the potential clinical utility and challenges 
of detecting and measuring itch sensitization. Measuring and distinguishing between alloknesis and 
hyperknesis with currently available methods is not a trivial task, and much remains unknown regarding 
neurophysiology of itch sensitization, and the interaction between itch and pain. Psychophysical studies in 
patients suffering from chronic itch have repeatedly shown mechano-sensory aberrations compatible with 
itch sensitization. However, these phenomena have only been sparsely documented in diseases other than 
AD. Further research needs to examine the mechanisms of itch sensitization, how current assessment 
methods can be optimized, why sensitization characteristics are pronounced only in certain patients within 




































































  15 
7. Acknowledgements 
HHA acknowledges support from the EliteForsk 2016 Travel-Stipend granted by the Danish Ministry of 
Higher Education and Science. Sinead Holden is acknowledged for proof reading the manuscript. The 






































































  16 
[1]  Akiyama T, Carstens MI, Ikoma A, Cevikbas F, Steinhoff M, Carstens E. Mouse model of touch-evoked 
itch (alloknesis). J Invest Dermatol 2012;132:1886–91. 
[2]  Akiyama T, Carstens MI, Piecha D, Steppan S, Carstens E. Nalfurafine suppresses pruitogen- and touch-
evoked scratching behavior in models of acute and chronic itch in mice. Acta Derm Venereol 2015;95:145–
50. 
[3]  Akiyama T, Merrill AW, Zanotto K, Carstens MI, Carstens E. Scratching behavior and Fos expression in 
superficial dorsal horn elicited by protease-activated receptor agonists and other itch mediators in mice. J 
Pharmacol Exp Ther 2009;329:945–51. 
[4]  Akiyama T, Nagamine M, Carstens MI, Carstens E. Behavioral model of itch, alloknesis, pain and allodynia 
in the lower hindlimb and correlative responses of lumbar dorsal horn neurons in the mouse. Neuroscience 
2014;266:38–46. 
[5]  Akiyama T, Nagamine M, Davoodi A, Ivanov M, Carstens MI, Carstens E. Innocuous warming enhances 
peripheral serotonergic itch signaling and evokes enhanced responses in serotonin-responsive dorsal horn 
neurons in the mouse. J Neurophysiol 2017;117:251–9. 
[6]  Akiyama T, Nguyen T, Curtis E, Nishida K, Devireddy J, Delahanty J, Carstens MI, Carstens E. A central 
role for spinal dorsal horn neurons that express neurokinin-1 receptors in chronic itch. Pain 2015;156:1240–
6. 
[7]  Andersen HH, Arendt-Nielsen L, Elberling J. Topical capsaicin 8% for the treatment of neuropathic itch 
conditions. Clin Exp Dermatol 2017;42:596–8. 
[8]  Andersen HH, Elberling J, Arendt-Nielsen L. Human Surrogate Models of Histaminergic and Non-
histaminergic Itch. Acta Derm Venereol 2015;95:771–7. 
[9]  Andersen HH, Elberling J, Sharma N, Hauberg LE, Gazerani P, Arendt-Nielsen L. Histaminergic and non-
histaminergic elicited itch is attenuated in capsaicin-evoked areas of allodynia and hyperalgesia: A healthy 
volunteer study. Eur J Pain 2017;21:1098–109. 
[10]  Andersen HH, Elberling J, Sølvsten H, Yosipovitch G, Arendt-Nielsen L. Nonhistaminergic and mechanical 
itch sensitization in atopic dermatitis. Pain 2017;158:1780–91. 
[11]  Andersen HH, Elberling J, Lo Vecchio S, Arendt-Nielsen L. Topography of itch: evidence of distinct coding 
for pruriception in the trigeminal nerve. Itch 2016;1:1–10. 
[12]  Andersen HH, van Laarhoven AIM, Elberling J, Arendt-Nielsen L. Modulation of Itch by Conditioning Itch 
and Pain Stimulation in Healthy Humans. J Pain 2017;18. 
[13]  Andersen HH, Marker JB, Hoeck EA, Elberling J, Arendt-Nielsen L. Antipruritic effect of pretreatment with 
topical capsaicin 8% on histamine- and cowhage-evoked itch in healthy volunteers: a randomized, vehicle-
controlled, proof-of-concept trial. Br J Dermatol 2017;177:107–16. 
[14]  Andersen HH, Melholt C, Hilborg SD, Jerwiarz A, Randers A, Simoni A, Elberling J, Arendt-Nielsen L. 
Antipruritic Effect of Cold-induced and Transient Receptor Potential-agonist-induced Counter-irritation on 
Histaminergic Itch in Humans. Acta Derm Venereol 2017;97:63–70. 


































































  17 
Patches in the Treatment of Chronic Pruritus in 3 Patients with Notalgia Paresthetica. Ann Dermatol 
2016;28:86–9. 
[16]  Andersen HH, Vecchio S Lo, Elberling J, Yosipovitch G, Arendt-Nielsen L. UVB and NGF-induced 
cutaneous sensitization in humans selectively augment cowhage and histamine-induced pain and mechanical 
hyperknesis. Exp Dermatol 2018:[Accepted-In press]. 
[17]  Andrew D, Greenspan JD. Mechanical and Heat Sensitization of Cutaneous Nociceptors After Peripheral 
Inflammation in The Rat. J Neurophysiol 1999;82:2649–56. 
[18]  Arendt-Nielsen L, Graven-Nielsen T. Translational musculoskeletal pain research. Best Pract Res Clin 
Rheumatol 2011;25:209–26. 
[19]  Arendt-Nielsen L, Nie H, Laursen MB, Laursen BS, Madeleine P, Simonsen OH, Graven-Nielsen T. 
Sensitization in patients with painful knee osteoarthritis. Pain 2010;149:573–81. 
[20]  Arendt-Nielsen L, Yarnitsky D. Experimental and clinical applications of quantitative sensory testing 
applied to skin, muscles and viscera. J Pain 2009;10:556–72. 
[21]  Atanassoff PG, Brull SJ, Zhang J, Greenquist K, Silverman DG, Lamotte RH. Enhancement of experimental 
pruritus and mechanically evoked dysesthesiae with local anesthesia. Somatosens Mot Res 1999;16:291–8. 
[22]  Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. 
Lancet Neurol 2010;9:807–19. 
[23]  Baron R, Hans G, Dickenson AH. Peripheral input and its importance for central sensitization. Ann Neurol 
2013;74:630–6. 
[24]  Baron R, Maier C, Attal N, Binder A, Bouhassira D, Cruccu G, Kennedy JD, Magerl W, Mainka T, Reimer 
M, Rice ASC, Sommer C, Thomas T. Peripheral neuropathic pain : a mechanism-related organizing 
principle based on sensory profiles. 2017;158. 
[25]  Baron R, Schwarz K, Kleinert A, Schattschneider J, Wasner G. Histamine-induced itch converts into pain in 
neuropathic hyperalgesia. Neuroreport 2001;12:3475–8. 
[26]  Le Bars D, Dickenson AH, Besson J-M. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal 
horn convergent neurones in the rat. Pain 1979;6:283–304. 
[27]  Baumann TK, Simone DA, Shain CN, LaMotte RH. Neurogenic hyperalgesia: the search for the primary 
cutaneous afferent fibers that contribute to capsaicin-induced pain and hyperalgesia. J Neurophysiol 
1991;66:212–27. 
[28]  Beltrani VS. The clinical spectrum of atopic dermatitis. J Allergy Clin Immunol 1999;104:S87–98. 
[29]  Berger TG, Steinhoff M. Pruritus in elderly patients-eruptions of senescence. Semin Cutan Med Surg 
2011;30:113–7. 
[30]  Bian D, Nichols ML, Ossipov MH, Lai J, Porreca F. Characterization of the antiallodynic efficacy of 
morphine in a model of neuropathic pain in rats. Neuroreport 1995;6:1981–4. 
[31]  Bickford RGL. Experiments relating to the itch sensation, it’s peripheral mechanism, and central pathays. 
Clin Sci 1938;3:377–86. 


































































  18 
Tucker SJ, Bennett DLH. Rare Nav1.7 variants associated with painful diabetic peripheral neuropathy. Pain 
2017;0:1. 
[33]  Bourane S, Duan B, Koch SC, Dalet A, Britz O, Garcia-Campmany L, Kim E, Cheng L, Ghosh A, Ma Q, 
Goulding M. Gate control of mechanical itch by a subpopulation of spinal cord interneurons. Science 
2015;350:550–4. 
[34]  Brenaut E, Garlantezec R, Talour K, Misery L. Itch characteristics in five dermatoses: Non-atopic eczema, 
atopic dermatitis, urticaria, psoriasis and scabies. Acta Derm Venereol 2013;93:573–4. 
[35]  van den Broeke EN, Lambert J, Huang G, Mouraux A. Central Sensitization of Mechanical Nociceptive 
Pathways Is Associated with a Long-Lasting Increase of Pinprick-Evoked Brain Potentials. Front Hum 
Neurosci 2016;10:1–10. 
[36]  Brull SJ, Atanassoff PG, Silverman DG, Zhang J, Lamotte RH. Attenuation of experimental pruritus and 
mechanically evoked dysesthesiae in an area of cutaneous allodynia. Somatosens Mot Res 1999;16:299–
303. 
[37]  Campbell J, Meyer R. Mechanisms of neuropathic pain. Neuron 2006;52:77–92. 
[38]  Carstens E. Many parallels between itch and pain research. Eur J Pain 2016;20:5–7. 
[39]  Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman R, Truini A, Attal N, 
Finnerup NB, Eccleston C, Kalso E, Bennett DL, Dworkin RH, Raja SN. Neuropathic pain. Nat Rev Dis 
Prim 2017;3:17002. 
[40]  Cowan A, Kehner GB, Inan S. Targeting Itch with Ligands Selective for κ Opioid Receptors. Handb Exp 
Pharmacol 2015;226:291–314. 
[41]  Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: 
Component analysis of atopic itch using the ‘Eppendorf Itch Questionnaire’. Int Arch Allergy Immunol 
2001;124:326–31. 
[42]  Davidson S, Giesler GJ. The multiple pathways for itch and their interactions with pain. Trends Neurosci 
2010;33:550–8. 
[43]  Davidson S, Zhang X, Khasabov SG, Moser HR, Honda CN, Simone D a, Giesler GJ. Pruriceptive 
spinothalamic tract neurons: physiological properties and projection targets in the primate. J Neurophysiol 
2012;108:1711–23. 
[44]  Davidson S, Zhang X, Khasabov SG, Simone DA, Giesler GJ. Relief of itch by scratching: State-dependent 
inhibition of primate spinothalamic tract neurons. Nat Neurosci 2009;12:544–6. 
[45]  Dawn A, Papoiu ADP, Chan YH, Rapp SR, Rassette N, Yosipovitch G. Itch characteristics in atopic 
dermatitis: Results of a web-based questionnaire. Br J Dermatol 2009;160:642–4. 
[46]  Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH. The effect of 
oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, 
placebo-controlled phenotype-stratified study. Pain 2014;155:2263–73. 
[47]  Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH. The effect of 


































































  19 
placebo-controlled phenotype-stratified study. Pain 2014;155:2263–73. 
[48]  Fruhstorfer H, Hermanns M, Latzke L. The effects of thermal stimulation on clinical and experimental itch. 
Pain 1986;24:259–69. 
[49]  Fukuoka M, Miyachi Y, Ikoma A. Mechanically evoked itch in humans. Pain 2013;154:897–904. 
[50]  Galor A, Zlotcavitch L, Walter SD, Felix ER, Feuer W, Martin ER, Margolis TP, Sarantopoulos KD, Levitt 
RC. Dry eye symptom severity and persistence are associated with symptoms of neuropathic pain. Br J 
Ophthalmol 2015;99:665–8. 
[51]  Goon ATJ, Yosipovitch G, Chan YH, Goh CL. Clinical characteristics of generalized idiopathic pruritus in 
patients from a tertiary referral center in Singapore. Int J Dermatol 2007;46:1023–6. 
[52]  Graven-Nielsen T, Wodehouse T, Langford RM, Arendt-Nielsen L, Kidd BL. Normalization of widespread 
hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee 
replacement. Arthritis Rheum 2012;64:2907–16. 
[53]  Green BG. Spatial summation of chemical irritation and itch produced by topical application of capsaicin. 
Percept Psychophys 1990;48:12–8. 
[54]  Handwerker HO. Pain and allodynia, itch and alloknesis: An alternative hypothesis. APS J 1992;1:135–8. 
[55]  Hansson P, Backonja M, Bouhassira D. Usefulness and limitations of quantitative sensory testing: Clinical 
and research application in neuropathic pain states. Pain 2007;129:256–9. 
[56]  Hawro T, Lehmann S, Altrichter S, Fluhr JW, Zuberbier T, Church MK, Maurer M, Metz M. Skin 
provocation tests may help to diagnose atopic dermatitis. Allergy Eur J Allergy Clin Immunol 
2016;71:1745–52. 
[57]  Henrich F, Magerl W, Klein T, Greffrath W, Treede R-D. Capsaicin-sensitive C- and A-fibre nociceptors 
control long-term potentiation-like pain amplification in humans. Brain 2015;138:2505–20. 
[58]  Heyer G, Dotzer M, Diepgen TL, Handwerker HO. Opiate and H1 antagonist effects on histamine induced 
pruritus and alloknesis. Pain 1997;73:239–43. 
[59]  Heyer G, Ulmer FJ, Schmitz J, Handwerker HO. Histamine-induced itch and alloknesis (itchy skin) in atopic 
eczema patients and controls. Acta Derm Venereol 1995;75:348–52. 
[60]  Heyer G, Vogelgsang M, Hornstein OP. Acetylcholine is an inducer of itching in patients with atopic 
eczema. J Dermatol 1997;24:621–5. 
[61]  Hidaka T, Ogawa E, Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Fujimura T, Aiba S, Nakayama 
K, Okuyama R, Yamamoto M. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution 
via induction of the neurotrophic factor artemin. Nat Immunol 2017;18:64–73. 
[62]  Hoeck EA, Marker JB, Gazerani P, H Andersen H, Arendt-Nielsen L. Preclinical and human surrogate 
models of itch. Exp Dermatol 2016;25:750–7. 
[63]  Hosogi M, Schmelz M, Miyachi Y, Ikoma A. Bradykinin is a potent pruritogen in atopic dermatitis: a switch 
from pain to itch. Pain 2006;126:16–23. 
[64]  IASP Taxonomy - Pain Terms. Part III Pain Terms, A Curr List with Defin Notes Usage 2011. Available: 


































































  20 
[65]  Ikoma A, Fartasch M, Heyer G, Miyachi Y, Handwerker H, Schmelz M. Painful stimuli evoke itch in 
patients with chronic pruritus: central sensitization for itch. Neurology 2004;62:212–7. 
[66]  Ikoma A, Handwerker H, Miyachi Y, Schmelz M. Electrically evoked itch in humans. Pain 2005;113:148–
54. 
[67]  Ikoma A, Rukwied R, Ständer S, Steinhoff M, Miyachi Y, Schmelz M. Neuronal sensitization for histamine-
induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol 2003;139:1455–8. 
[68]  Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci 
2006;7:535–47. 
[69]  Ishiuji Y, Coghill RC, Patel TS, Dawn A, Fountain J, Oshiro Y, Yosipovitch G. Repetitive scratching and 
noxious heat do not inhibit histamine-induced itch in atopic dermatitis. Br J Dermatol 2008;158:78–83. 
[70]  Jiang Y-M, Huang C, Peng Z, Han S-L, Li W-G, Zhu MX, Xu T-L. Acidosis counteracts itch tachyphylaxis 
to consecutive pruritogen exposure dependent on acid-sensing ion channel 3. Mol Pain 2017;13:1–8. 
[71]  Johanek LM, Meyer R a, Hartke T, Hobelmann JG, Maine DN, LaMotte RH, Ringkamp M. Psychophysical 
and Physiological Evidence for Parallel Afferent Pathways Mediating the Sensation of Itch. J Neurosci 
2007;27:7490–7. 
[72]  Klede M. Central Origin of Secondary Mechanical Hyperalgesia. J Neurophysiol 2003;90:353–9. 
[73]  Koltzenburg M, Lundberg LE, Torebjörk HE. Dynamic and static components of mechanical hyperalgesia in 
human hairy skin. Pain 1992;51:207–19. 
[74]  Kumar K, Singh S. Neuraxial opioid-induced pruritus: An update. J Anaesthesiol Clin Pharmacol 
2013;29:303–7. 
[75]  van Laarhoven AIM, Kraaimaat FW, Wilder-Smith OH, van de Kerkhof PCM, Cats H, van Riel PLCM, 
Evers AWM. Generalized and symptom-specific sensitization of chronic itch and pain. J Eur Acad 
Dermatology Venereol 2007;21:1187–92. 
[76]  van Laarhoven AIM, Kraaimaat FW, Wilder-Smith OH, van de Kerkhof PCM, Evers AWM. Heterotopic 
pruritic conditioning and itch--analogous to DNIC in pain? Pain 2010;149:332–7. 
[77]  van Laarhoven AIM, Kraaimaat FW, Wilder-Smith OH, van Riel PLCM, van de Kerkhof PCM, Evers 
AWM. Sensitivity to itch and pain in patients with psoriasis and rheumatoid arthritis. Exp Dermatol 
2013;22:530–4. 
[78]  van Laarhoven AIM, Ulrich DJO, Wilder-Smith OH, van Loey NEE, Nieuwenhuis M, van der Wee NJA, 
Evers AWM. Psychophysiological Processing of Itch in Patients with Chronic Post-burn Itch: An 
Exploratory Study. Acta Derm Venereol 2016;96:613–8. 
[79]  Lamotte RH. Subpopulations of ‘Nocifensor Neurons’ Contributing to Pain and Allodynia, Itch and 
Alloknesis. Am Pain Soc J 1992;1:115–26. 
[80]  LaMotte RH. Encyclopedia of Pain - Allodynia and Alloknesis. Gebhart GF, Schmidt RF, editors Berlin, 
Heidelberg: Springer Berlin Heidelberg, 2013 p. 
[81]  LaMotte RH. Psychophysical and neurophysiological studies of chemically induced cutaneous pain and itch. 


































































  21 
[82]  LaMotte RH, Dong X, Ringkamp M. Sensory neurons and circuits mediating itch. Nat Rev Neurosci 
2014;15:19–31. 
[83]  LaMotte RH, Tsai EFP, Shain CN, Simone D a, Tsai EFP. Neurogenic hyperalgesia: psychophysical studies 
of underlying mechanisms. J Neurophysiol 1991;66:190–211. 
[84]  Latremoliere A, Woolf CJ. Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural 
Plasticity. J Pain 2009;10:895–926. 
[85]  Liang YF, Haake B, Reeh PW. Sustained sensitization and recruitment of rat cutaneous nociceptors by 
bradykinin and a novel theory of its excitatory action. J Physiol 2001;532:229–39. 
[86]  Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF. Cutaneous 
allodynia in the migraine population. Ann Neurol 2008;63:148–58. 
[87]  Liu Q, Sikand P, Ma C, Tang Z, Han L, Li Z, Sun S, LaMotte RH, Dong X. Mechanisms of Itch Evoked by 
beta-Alanine. J Neurosci 2012;32:14532–7. 
[88]  Liu T, Han Q, Chen G, Huang Y, Zhao L-X, Berta T, Gao Y-J, Ji R-R. Toll-like receptor 4 contributes to 
chronic itch, alloknesis, and spinal astrocyte activation in male mice. Pain 2016;157:806–17. 
[89]  Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. Pain 2008;137:473–7. 
[90]  Magerl W, Fuchs PN, Meyer RA, Treede RD. Roles of capsaicin-insensitive nociceptors in cutaneous pain 
and secondary hyperalgesia. Brain 2001;124:1754–64. 
[91]  Magerl W, Westerman RA, Möhner B, Handwerker HO. Properties of transdermal histamine iontophoresis: 
differential effects of season, gender, and body region. J Invest Dermatol 1990;94:347–52. 
[92]  Maier C, Baron R, Tölle TR, Binder  a, Birbaumer N, Birklein F, Gierthmühlen J, Flor H, Geber C, Huge V, 
Krumova EK, Landwehrmeyer GB, Magerl W, Maihöfner C, Richter H, Rolke R, Scherens  a, Schwarz  a, 
Sommer C, Tronnier V, Uçeyler N, Valet M, Wasner G, Treede R-D. Quantitative sensory testing in the 
German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients 
with different neuropathic pain syndromes. Pain 2010;150:439–50. 
[93]  Mainka T, Malewicz NM, Baron R, Enax-Krumova EK, Treede R-D, Maier C. Presence of hyperalgesia 
predicts analgesic efficacy of topically applied capsaicin 8% in patients with peripheral neuropathic pain. 
Eur J Pain 2016;20:116–29. 
[94]  Melzack R, Wall PDD. Pain mechanisms: a new theory. Surv Anesthesiol 1965;11:89. 
[95]  Merskey H. Pain Terms: a list of definitions and notes on usage. Pain 1979;6:247–52. 
[96]  Merskey H. Pain terms: A supplementary note. Pain 1982;14:205–6. 
[97]  Merskey H, Bogduk N. Classification of chronic pain. Descriptions of chronic pain syndromes and 
definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on 
Taxonomy. Pain Suppl 1986;3:S1-226. 
[98]  Meyer R a, Campbell JN. Myelinated nociceptive afferents account for the hyperalgesia that follows a burn 
to the hand. Science 1981;213:1527–9. 
[99]  Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, Pieper JO, Hain HS, Belknap JK, Hubert L, 


































































  22 
correlation analysis. Pain 1999;80:83–93. 
[100]  Moser HR, Giesler GJ. Itch and analgesia resulting from intrathecal application of morphine: contrasting 
effects on different populations of trigeminothalamic tract neurons. J Neurosci 2013;33:6093–101. 
[101]  Mu D, Deng J, Liu K-F, Wu Z-Y, Shi Y-F, Guo W-M, Mao Q-Q, Liu X-J, Li H, Sun Y-G. A central neural 
circuit for itch sensation. Science 2017;357:695–9. 
[102]  Murota H, Katayama I. Evolving understanding on the aetiology of thermally provoked itch. Eur J Pain 
2016;20:47–50. 
[103]  Namer B, Carr R, Johanek LM, Schmelz M, Handwerker HO, Ringkamp M. Separate Peripheral Pathways 
for Pruritus in Man. J Neurophysiol 2008;100:2062–9. 
[104]  Namer B, Reeh P. Scratching an itch. Nat Neurosci 2013;16:117–8. 
[105]  Nijs J, Malfliet A, Ickmans K, Baert I, Meeus M. Treatment of central sensitization in patients with 
‘unexplained’ chronic pain: an update. Expert Opin Pharmacother 2014;15:1671–83. 
[106]  Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): A new powerful method to 
combat itch. Pain 1997;71:49–55. 
[107]  Nilsson HJ, Psouni E, Carstam R, Schouenborg J. Profound inhibition of chronic itch induced by stimulation 
of thin cutaneous nerve fibres. J Eur Acad Dermatology Venereol 2004;18:37–43. 
[108]  Nir R-R, Granovsky Y, Yarnitsky D, Sprecher E, Granot M. A psychophysical study of endogenous 
analgesia: the role of the conditioning pain in the induction and magnitude of conditioned pain modulation. 
Eur J Pain 2011;15:491–7. 
[109]  O’Neill JL, Chan YH, Rapp SR, Yosipovitch G. Differences in itch characteristics between psoriasis and 
atopic dermatitis patients: Results of a web-based questionnaire. Acta Derm Venereol 2011;91:537–40. 
[110]  Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. Curr Opin 
Support Palliat Care 2014;8:143–51. 
[111]  Pall PS, Hurwitz OE, King BA, LaMotte RH. Psychophysical measurements of itch and nociceptive 
sensations in an experimental model of allergic contact dermatitis. J Pain 2015;16:741–9. 
[112]  Peirs C, Seal RP. Neural circuits for pain: Recent advances and current views. Science 2016;354:578–84. 
[113]  Pereira M, Lotts T, Dreyer T, Cremer A, Englbrecht J, Ringkamp M, Ständer S, Pogatzki-Zahn E. 
Somatosensory Dysfunctions in Patients with Chronic Pruritus. Abstr Eur Pain Fed 2015:P060. 
[114]  Pereira MP, Mühl S, Pogatzki-Zahn EM, Agelopoulos K, Ständer S. Intraepidermal Nerve Fiber Density: 
Diagnostic and Therapeutic Relevance in the Management of Chronic Pruritus: a Review. Dermatol Ther 
(Heidelb) 2016;6:509–17. 
[115]  Petersen KK, Arendt-Nielsen L, Simonsen O, Wilder-Smith O, Laursen MB. Presurgical assessment of 
temporal summation of pain predicts the development of chronic postoperative pain 12 months after total 
knee replacement. Pain 2015;156:55–61. 
[116]  Pongcharoen P, Fleischer ABB. An evidence-based review of systemic treatments for itch. Eur J Pain 
2016;20:24–31. 


































































  23 
excitability of MRGPRA3- and MRGPRD-positive nociceptors in a model of inflammatory itch and pain. 
Brain 2014;137:1039–50. 
[118]  Raputova J, Srotova I, Vlckova E, Sommer C, Üçeyler N, Birklein F, Rittner HL, Rebhorn C, Adamova B, 
Kovalova I, Kralickova Nekvapilova E, Forer L, Belobradkova J, Olsovsky J, Weber P, Dusek L, Jarkovsky 
J, Bednarik J. Sensory phenotype and risk factors for painful diabetic neuropathy. Pain 2017;158:2340–53. 
[119]  Rolke R, Baron R, Maier C, Tölle TR, Treede - D. R., Beyer A, Binder A, Birbaumer N, Birklein F, Bötefür 
IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihöfner C, Rolko C, Schaub C, 
Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research 
Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. Pain 2006;123:231–43. 
[120]  Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, Treede R-D. Quantitative sensory 
testing: a comprehensive protocol for clinical trials. Eur J Pain 2006;10:77–88. 
[121]  Rukwied RR, Main M, Weinkauf B, Schmelz M. NGF sensitizes nociceptors for cowhage- but not 
histamine-induced itch in human skin. J Invest Dermatol 2013;133:268–70. 
[122]  Sakai K, Sanders KM, Youssef MR, Yanushefski KM, Jensen L, Yosipovitch G, Akiyama T. Mouse model 
of imiquimod-induced psoriatic itch. Pain 2016;157:2536–43. 
[123]  Sandkühler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 2009;89:707–58. 
[124]  Schmelz M. Itch and pain differences and commonalities. Handb Exp Pharmacol 2015;227:286–301. 
[125]  Schmelz M. Opioid-induced pruritus. Mechanisms and treatment regimens. Anaesthesist 2009;58:61–5. 
[126]  Schmelz M. Quantitative sensory test correlates with neuropathy, not with pain. Pain 2018;0:1. 
[127]  Schneider G, Ständer S, Burgmer M, Driesch G, Heuft G, Weckesser M. Significant differences in central 
imaging of histamine-induced itch between atopic dermatitis and healthy subjects. Eur J Pain 2008;12:834–
41. 
[128]  Sikand P, Shimada SG, Green BG, LaMotte RH. Sensory responses to injection and punctate application of 
capsaicin and histamine to the skin. Pain 2011;152:2485–94. 
[129]  Simone DA. Comparison of Responses of Primate Spinothalamic Tract Neurons to Pruritic and Algogenic 
Stimuli. J Neurophysiol 2003;91:213–22. 
[130]  Simone D a., Baumann TK, LaMotte RH. Dose-dependent pain and mechanical hyperalgesia in humans 
after intradermal injection of capsaicin. Pain 1989;38:99–107. 
[131]  Simone D a, Alreja M, LaMotte RH. Psychophysical studies of the itch sensation and itchy skin 
(‘alloknesis’) produced by intracutaneous injection of histamine. Somatosens Mot Res 1991;8:271–9. 
[132]  Simone DA, Sorkin LS, Oh U, Chung JM, Owens C, LaMotte RH, Willis WD. Neurogenic hyperalgesia: 
Central neural correlates in responses of spinothalamic tract neurons. J Neurophysiol 1991;66:228–46. 
[133]  Skou ST, Graven-Nielsen T, Rasmussen S, Simonsen OH, Laursen MB, Arendt-Nielsen L. Widespread 
sensitization in patients with chronic pain after revision total knee arthroplasty. Pain 2013;154:1588–94. 
[134]  Ständer S, Schmelz M. Chronic itch and pain--similarities and differences. Eur J Pain 2006;10:473–8. 
[135]  Ständer S, Weisshaar E, Mettang T, Szepietowski J, Carstens E, Ikoma A, Bergasa N, Gieler U, Misery L, 


































































  24 
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch. Acta Derm 
Venereol 2007;87:291–4. 
[136]  Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, Luger T a, Schmelz M. Proteinase-
activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003;23:6176–
80. 
[137]  Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci 2010;11:823–36. 
[138]  Treede R-D. Allodynia (clinical, experimental). In: Schmidt RF, William D., editors. Encyclopedia of pain. 
Springer Berlin Heidelberg New York, 2013. pp. 49–55. 
[139]  Vaegter HB, Palsson TS, Graven-Nielsen T. Facilitated Pronociceptive Pain Mechanisms in Radiating Back 
Pain Compared With Localized Back Pain. J Pain 2017;18:973–83. 
[140]  Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, Immaneni S, White T, Kantor R, Hsu DY, 
Silverberg JI. Burden of skin pain in atopic dermatitis. Ann Allergy, Asthma Immunol 2017;119:548–52. 
[141]  Wahlgren CF. Itch and atopic dermatitis: An overview. J Dermatol 1999;26:770–9. 
[142]  Wahlgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol 
1991;165:1–53. 
[143]  Wahlgren CF, Ekblom A. Perception of histamine-induced itch elicited in three different skin regions. Acta 
Derm Venereol 1991;71:205–8. 
[144]  Wahlgren CF, Hagermark O, Bergstrom R. Patients’ perception of itch induced by histamine, compound 
48/80 and wool fibres in atopic dermatitis. Acta Derm Venereol 1990;71:488–94. 
[145]  Wang X-L, Tian B, Huang Y, Peng X-Y, Chen L-H, Li J-C, Liu T. Hydrogen sulfide-induced itch requires 
activation of Cav3.2 T-type calcium channel in mice. Sci Rep 2015;5:16768. 
[146]  Weisshaar E, Diepgen TL, Bruckner T, Fartasch M, Kupfer J, Lobcorzilius T, Ring J, Scheewe S, Scheidt R, 
Schmid-Ott G, Schnopp C, Staab D, Szczepanski R, Werfel T, Wittenmeier M, Wahn U, Gieler U. Itch 
intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): Correlations with quality 
of life, coping behaviour and SCORAD severity in 823 children. Acta Derm Venereol 2008;88:234–9. 
[147]  Weisshaar E, Dunker N, Gollnick H. Topical capsaicin therapy in humans with hemodialysis-related 
pruritus. Neurosci Lett 2003;345:192–4. 
[148]  Weisshaar E, Gieler U, Kupfer J, Furue M, Saeki H, Yosipovitch G. Questionnaires to Assess Chronic Itch: 
A Consensus Paper of the Special Interest Group of the International Forum on the Study of Itch. Acta Derm 
Venereol 2012;92:493–6. 
[149]  Weisshaar E, Heyer G, Forster C, Handwerker HO. Effect of topical capsaicin on the cutaneous reactions 
and itching to histamine in atopic eczema compared to healthy skin. Arch Dermatol Res 1998;290:306–11. 
[150]  Witting N, Svensson P, Arendt-Nielsen L, Jensen TS. Differential effect of painful heterotopic stimulation 
on capsaicin- induced pain and allodynia. Brain Res 1998;801:206–10. 
[151]  Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011;152:S2–15. 
[152]  Wooten M, Weng H-J, Hartke T V, Borzan J, Klein AH, Turnquist B, Dong X, Meyer RA, Ringkamp M. 


































































  25 
[153]  Xu AZ, Tripathi S V., Kau AL, Schaffer A, Kim BS. Immune dysregulation underlies a subset of patients 
with chronic idiopathic pruritus. J Am Acad Dermatol 2016;74:1017–20. 
[154]  Yarnitsky D. Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance 
for acute and chronic pain states. Curr Opin Anaesthesiol 2010;23:611–5. 
[155]  Yarnitsky D, Bouhassira D, Drewes AM, Fillingim RB, Granot M, Hansson P, Landau R, Marchand S, 
Matre D, Nilsen KB, Stubhaug A, Treede RD, Wilder-Smith OH. Recommendations on practice of 
conditioned pain modulation (CPM) testing. Eur J Pain 2015;19:805–6. 
[156]  Yarnitsky D, Granot M. Quantitative sensory testing. Handb Clin Neurol 2006;81:397–409. 
[157]  Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation 
predicts duloxetine efficacy in painful diabetic neuropathy. Pain 2012;153:1193–8. 
[158]  Yosipovitch G, Ansari N, Goon A, Chan YH, Goh CL. Clinical characteristics of pruritus in chronic 
idiopathic urticaria. Br J Dermatol 2002;147:32–6. 
[159]  Yosipovitch G, Bernhard JD. Chronic Pruritus. N Engl J Med 2013;368:1625–34. 
[160]  Yosipovitch G, Fast K, Bernhard JD. Noxious Heat and Scratching Decrease Histamine-Induced Itch and 
Skin Blood Flow. J Invest Dermatol 2005;125:1268–72. 
[161]  Yosipovitch G, Greaves MW, Schmelz M. Review Itch. Lancet 2003;361:690–4. 
[162]  Yudina MM, Toropina GG, Lvov AN, Gieler U. Innovative neurophysiological methods in itch research: 
Longlatency evoked potentials after electrical and thermal stimulation in patients with atopic dermatitis. 
Acta Derm Venereol 2011;91:656–9. 
[163]  Ziegler EA, Magerl W, Meyer RA, Treede RD. Secondary hyperalgesia to punctate mechanical stimuli. 
Central sensitization to A-fibre nociceptor input. Brain 1999;122:2245–57. 
[164]  Zylka MJ, Rice FL, Anderson DJ. Topographically distinct epidermal nociceptive circuits revealed by 




































































  26 
Figure legends 
 
Figure 1 – Conceptual illustrations of the sensitized state constituting alloknesis (A), hyperknesis and 
algoknesis (B). A) Alloknesis comprises a switch in perception of a normally innocuous stimulus such as light 
stroking of the skin, which additionally or alternatively becomes itch evoking. B) Hyperknesis comprises a leftward 
shift in the stimulus-response curve for a normally itching stimulus while the modality-switch phenomenon in which 
a predominantly pain-evoking stimulus is perceived as itching is herein referred to as ‘algoknesis’ (marked with §). 
The stimulus intensity scale (marked with *) on the x-axis of plot A is not continuous and far from all modalities 
evoke both itch and pain.  
 
Figure 2 – Models of itch sensitization mechanisms occurring in the periphery and in the spinal dorsal horn. 
Lightning bolts denotes components of the modeled pathways where sensitization may occur. Potential sites of 
disinhibition are marked with red stop-symbols. A) Following a barrage from a pruriceptive primary afferent (red) a 
facilitatory interneuron (green) that receives convergent input from an Aβ-fiber (blue), becomes sensitized. 
Consequently, the pruriceptive projection neuron exhibit responsiveness to light touch stimuli, such as brush strokes, 
leading to the abnormal perception of itch (alloknesis). B) Following a barrage from a pruriceptive primary afferent 
(red) a facilitatory interneuron (green) that receives convergent input from a mechanosensitive nociceptor (blue), 
becomes sensitized. Consequently, the pruriceptive projection neuron exhibit increased responsiveness to pinprick 
stimuli, leading to de novo or increased perception of itch in conjunction with the normal pricking sensation. A 
notable distinction between A) and B) is that for B) primary hyperknesis could be mediated by sensitization of the 
pruriceptive primary afferent (red) itself by increased sensitivity to pinprick stimuli or by direct convergence of the 
mechanosensitive nociceptor. C) Histamine-induced pruriception engages an inhibitory interneuron (green) below 
threshold potential, which in turn becomes receptive to input from mechano-nociceptive units (blue). Subsequently, 
a noxious counter-stimulus such as scratching inhibits signaling from the pruriceptive projection neuron (adapted 
from “and-gate” model 42). Note that scratch-induced inhibition of pruriceptive STT neurons occur in a state-
dependent manner, i.e. inhibition only occurs during pruritogen-evoked activity, but not during spontaneous or 
algogen-evoked firing (shown for histamine) 44. In chronic itch conditions indirect evidence suggest that scratch-
evoked itch inhibition is blunted 69,127. Such a blunting of normal itch inhibition could result from: disinhibition of 
the depicted spinal circuitry, loss of epidermal nerve fiber density resulting in decreased input to the gate (reduced 
fiber density is a frequent finding in chronic itch conditions), or involve altered of supraspinal modulation (not 
depicted). While the stimuli examples given above are derived from human surrogate itch model studies the initial 
driving itch might as well be “endogenous” pruriceptive signaling, e.g. associated with atopic dermatitis, 
neuropathic itch etc.  
 
Figure 3 – The inter-variability of hyperknesis in patients with atopic dermatitis compared with data from 
healthy controls. The full study, including the methodology used to assess and rate hyperknesis, and a simplified 
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hyperknesis probed at baseline in lesional (dark red) and non-lesional (bright red) skin of patients with atopic 
dermatitis  (n = 25) compared to healthy controls (n = 25). Data from homologous healthy control areas is pooled 
(50 data points). B) Shows the same as (A), but here hyperknesis was assessed after itch from a cowhage 
provocation had subsided (again conducted intra and extra-lesionally). Bottom plots shows the intra-lesional 
responses to mechanical itch provocations correlated with the responses to extra-lesional provocations at baseline 
(C) and following a cowhage provocation (D). Marked grey areas indicate the healthy control average +2 standard 
deviations (SD), thus constituting a limit at which hyperknesis on an individual level can be detected. Note that 
significant individually determined hyperknesis only affects 20-52% of the patients depending on the assessment 
method (>1.96 SDs above the average healthy control response) and that patients either have sensitization restricted 
to their lesions or affecting both their lesional and non-lesional skin. Only n = 1/50 showed sensitization selectively 


































































Figure 1_revised Click here to download Figure Fig. 1_revised.png 
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Sensitization processes Examples 
of studies Peripheral Central 




Aβ-fibers  X 63,131,144 




[Aδ/PmC-fibers] [X] X 10,65,75 
Warmth induced / 









[Aδ/PmC-fibers] [X] [X] 5,65,102,111 




C-fibers (CMi and 
PmC) 
X [X] 10,56,67,144 
 
Table 1 – Itch sensitization phenomenon and proposed mechanisms. Square bracket “[]” indicates 
conceivable, but not yet established, mechanisms. CMi = C-mechano-insensitive fibers, PmC = Polymodal C-
fibers. 1 Principally, alloknesis could occur to non-mechanical stimuli, such as gentle warming, but this example 
is not yet well established mechanistically. 2 Algoknesis is used in the present review to denote itch occurring in 






Provocations / causative 
condition(s) 
Mechanical 
itch dysesthesia  











s Pruritogen injections, dry skin, contact 
dermatitis, psoriasis model, atopic 
dermatitis model, genetic models 




N/A [Medium intensity von Frey filaments or 









s Pruritogens (e.g. histamine, cowhage) 
electrical/mechanical stimulation, 
contact dermatitis model  
Alloknesis 
Brush strokes (mapping or single stimuli), von 
Frey filaments or cotton wisp 
63,66,111,128 













Atopic dermatitis, renal insufficiency 
associated pruritus, post-burn pruritus 
contact dermatitis, neuropathic itch  
Alloknesis 
No preceding itch provocation: e.g. to wool, 
brush strokes, synthetic fabrics etc., After itch 
provocation: brush strokes, cotton swab/wisp, 




No preceding itch provocation: wool, pinprick 
stimulators. After itch provocation: Pinprick 
stimulators (blunt), weighted needles (sharp), 
von Frey filaments  
10,65,75,78,144 
 
Table 2 – Methodology used to assess mechanical itch dysesthesias. The table provides and overview of 
methods by which alloknesis and hyperknesis have been studied in animals, human experimental models and in 
patients suffering from chronic itch diseases. In the row clinical itch conditions, “no preceding itch provocation” 
refers to assessment of allo/hyperknesis without any eliciting itch provocation, while “after itch provocation” 
refers to assessment of the itch dysesthesia following an itch provocation. Square brackets denote a potential 










Observed mechanical itch dysesthesia 
Lesional Non-lesional 
Wahlgren et 




No preceding itch provocation:↑Hyperknesis  
Unclear whether lesional and/or extra-lesional 






After itch provocation: 
↓Alloknesis 
Weisshaar et 





After itch provocation: 
↓Alloknesis 
Weisshaar et 






After itch provocation:  
→Alloknesis 






No preceding itch provocation: 
↑Hyperknesis (AD)  
→ Hyperknesis (psoriasis) 
No preceding itch provocation  
↑Hyperknesis (peri-lesional)4 
→ Hyperknesis (extra-lesional)4 
Ikoma et al. 
2005 66 
AD 
Sensory brush and pin 
prick stimulators  
(Spatial approach2) 
N/A 
Evoked: → Alloknesis 
Evoked: → Hyperknesis5 





No preceding itch provocation:
↑Alloknesis 
No preceding itch provocation: 
→Alloknesis 
Laarhoven et 
al. 2007 75 
AD 
Von Frey stimulators 
(Intensity approach) 
No preceding itch provocation: 
↑Hyperknesis3 
No preceding itch provocation: 
↑Hyperknesis4 
Andersen et 
al. 2017 10 
AD 
Von Frey stimulators 
(Intensity approach) 
No preceding itch provocation: 
↑Hyperknesis 
No preceding itch provocation:
↑Hyperknesis 
 
Table 3 – Results from studies on mechanical itch dysesthesias in patients with chronic itch versus 
healthy controls. The table list notable studies assessing alloknesis and/or hyperknesis in patients with itch 
conditions as well as the methods applied in each study. Notice that the vast majority of studies have been 
conducted in atopic dermatitis (AD). Caption: 1 = Following an iontophoretic histamine provocation, 2 = 
Following electrically induced itch, 3 = predominantly intra-lesional, 4 = in AD only, 5 = a trend toward more 
hyperknesis in patients was observed, 6 = predominantly non-lesional. Arrows: sensitivity in patients vs. 
controls: ↑= significantly increased responses in patients↓= significantly decreased responses in patients, → 
no significant differences. “No preceding itch provocation” refers to assessment of allo/hyperknesis without any 
preceding itch provocation, while “after itch provocation” refers to assessment of the itch dysesthesia following 
an itch provocation 
 
Table 3
